Hepion Pharmaceuticals, Inc. (HEPA) stock
Close on Oct 19, 2026Market cap $7.26MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $7.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.30M
- EPS, diluted
- -$0.88
- Book value per share
- -$0.06
- Diluted shares
- 71M
Trading
- Previous close
- $0.10
- Open
- $0.10
- Day's range
- $0.10 – $0.11
- Volume
- 18,391
- Average volume (20 days)
- 45,124
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | HEPA | S&P 500 | Difference | HEPA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +32.8% | +0.6% | +32.1 pts | ||
| 3 months | +67.4% | +3.4% | +64.0 pts | ||
| Year to date | +70.2% | +13.3% | +56.9 pts | ||
| 1 year | +43.8% | +16.6% | +27.2 pts | ||
| 3 years | -100.0% | +86.4% | −186.3 pts | -92.3% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -85.4% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -80.4% | +15.4% |
Twelve years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Hepion Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- Update
- Update
About Hepion Pharmaceuticals
Pharmaceutical Preparations
Hepion Pharmaceuticals, Inc. operates as a medical diagnostic company focused on diagnostic solutions. The company previously concentrated on developing drug therapies for chronic liver conditions, specifically its cyclophilin inhibitor rencofilstat, before divesting all related patent assets, clinical data, and drug materials. Currently, Hepion in-licenses diagnostic tests covering conditions such as celiac disease, respiratory multiplex infections, Helicobacter pylori, and hepatocellular carcinoma, alongside licensed liver disease diagnostic assets. It targets healthcare markets seeking clinical diagnostic tools.
Company profile, executives and historyHepion Pharmaceuticals stock: common questions
What is Hepion Pharmaceuticals's stock price?
HEPA closed at $0.10 on Oct 19, 2026, down 1.45% on the day.
What is Hepion Pharmaceuticals's market cap?
Hepion Pharmaceuticals was worth $7.26M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is HEPA's P/E ratio?
Hepion Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$0.88), so it has no meaningful P/E ratio.
Does Hepion Pharmaceuticals pay a dividend?
No. Hepion Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has HEPA stock performed over the past year?
Including dividends, HEPA returned +43.8% over the past year, against +16.6% for the S&P 500.
Who are Hepion Pharmaceuticals's competitors?
Companies most similar to Hepion Pharmaceuticals by business, industry and size include JAGX, ONCO, RDHL, MDGL, EOCN.
See a number that looks wrong?